SCHEMBL3052938

SCHEMBL3052938

CCc1ccc(C(=O)c2c[nH]c3cccc(OC)c23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 2/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ MTNR1A P48039 1/20 0.46
▸ MTNR1B P49286 1/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ KIF20A O95235 1/20 0.44
▸ CLK1 P49759 1/20 0.44
▸ DYRK1A Q13627 1/20 0.44
▸ HTR2A P28223 1/20 0.44
▸ NR4A2 P43354 1/20 0.44
▸ CTNNB1 P35222 1/20 0.43
▸ WNT3A P56704 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ HTR6 P50406 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HDAC3 O15379 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3041131 0.85 KMT2A (0.51) TP53SMN1; SMN2NPSR1MTNR1AMTNR1B
SCHEMBL3041220 0.83 GAA (0.46) TP53SMN1; SMN2NPSR1HTR2ANR4A2
SCHEMBL3411024 0.82 CFTR (0.42) TP53SMN1; SMN2NPSR1RAB9ANPC1
SCHEMBL1562284 0.80 TUBB1 (0.62) —
SCHEMBL10930498 0.79 NR4A2 (0.51) MTNR1AMTNR1BRAB9AHTR2ANR4A2
SCHEMBL19997209 0.79 CTNNB1 (0.52) MTNR1AMTNR1BRAB9ANPC1KIF20A
SCHEMBL5329797 0.78 NR4A2 (0.68) MTNR1AMTNR1BRAB9ANPC1KIF20A
SCHEMBL12610974 0.78 SMN1; SMN2 (0.51) TP53SMN1; SMN2NPSR1MTNR1AMTNR1B
SCHEMBL13110428 0.78 SLC5A2 (0.73) —
SCHEMBL11545107 0.77 MTNR1A (0.56) MTNR1AMTNR1BRAB9ANPC1KIF20A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820630-B2 Substituted indole-O-glucosides JANSSEN PHARMACEUTICA NV (BE) 2010-10-26 — — US disclosed
US-20100009900-A1 SUBSTITUTED INDOLE-O-GLUCOSIDES BEAVERS MARY PAT 2010-01-14 — — US disclosed
EP-1680131-A4 SUBSTITUTED INDOLE-O-GLUCOSIDES JANSSEN PHARMACEUTICA NV (BE) 2009-05-27 — — EP disclosed
US-20090105164-A1 SUBSTITUTED INDOLE-O-GLUCOSIDES BEAVERS MARY PAT 2009-04-23 — — US disclosed
US-7511022-B2 Substituted indole-O-glucosides JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-31 — — US disclosed
US-20060293251-A1 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-28 — — US disclosed
US-7129220-B2 Substituted indole-O-glucosides JANSSEN PHARMACEUTICA N.V (BE) 2006-10-31 — — US disclosed
EP-1680131-A2 SUBSTITUTED INDOLE-O-GLUCOSIDES JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-19 — — EP disclosed
US-20050037981-A1 Substituted indole-O-glucosides JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-17 — — US disclosed
WO-2005012243-A2 SUBSTITUTED INDOLE-O-GLUCOSIDES JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009900-A1 SUBSTITUTED INDOLE-O-GLUCOSIDES GPR119, PYGL, IAPP TP53 3072/4885SMN1; SMN2 3854/4885NPSR1 434/4885
US-20090105164-A1 SUBSTITUTED INDOLE-O-GLUCOSIDES GPR119, PYGL, IAPP TP53 3072/4885SMN1; SMN2 3854/4885NPSR1 434/4885
US-20050037981-A1 Substituted indole-O-glucosides GPR119, PYGL, IAPP TP53 3072/4885SMN1; SMN2 3854/4885NPSR1 434/4885
US-20060293251-A1 Substituted indazole-O-glucosides GPR119, PYGL, GYS2 TP53 2650/4885SMN1; SMN2 4335/4885NPSR1 2192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback